Workflow
Avidity Biosciences, Inc. (RNA) Reports Q1 Loss, Misses Revenue Estimates
RNAAvidity Biosciences(RNA) ZACKS·2025-05-08 23:00

Company Performance - Avidity Biosciences reported a quarterly loss of 0.90pershare,slightlyworsethantheZacksConsensusEstimateofalossof0.90 per share, slightly worse than the Zacks Consensus Estimate of a loss of 0.88, and compared to a loss of 0.79pershareayearago,indicatinganegativeearningssurpriseof−2.270.79 per share a year ago, indicating a negative earnings surprise of -2.27% [1] - The company posted revenues of 1.57 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 46.68%, and down from 3.54millioninthesamequarterlastyear[2]−Overthelastfourquarters,AvidityhassurpassedconsensusEPSestimatesthreetimes,buthasonlytoppedconsensusrevenueestimatesonce[2]MarketComparison−AvidityBiosciencesshareshavedeclinedapproximately103.54 million in the same quarter last year [2] - Over the last four quarters, Avidity has surpassed consensus EPS estimates three times, but has only topped consensus revenue estimates once [2] Market Comparison - Avidity Biosciences shares have declined approximately 10% since the beginning of the year, while the S&P 500 has seen a decline of -4.3% [3] Future Outlook - The current consensus EPS estimate for the upcoming quarter is -0.86 on revenues of 2.1million,andforthecurrentfiscalyear,itis−2.1 million, and for the current fiscal year, it is -3.90 on revenues of $9.25 million [7] - The estimate revisions trend for Avidity Biosciences is currently favorable, leading to a Zacks Rank 2 (Buy) for the stock, suggesting it is expected to outperform the market in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Avidity belongs, is currently in the top 33% of over 250 Zacks industries, indicating a positive outlook for stocks within this sector [8]